© Copyright Our Wall
Cold Chain Logistics Market Size 2035 Covid-19 Impact on Healthcare Industry Global Analysis by Size, Trends, Growth, Share, Business, Key Players and Regional Forecast latest study published by Roots Analysis.
Global” Cold Chain Logistics Market “2035
industry research report gives Advancement strategies and plans are talked
about just as assembling procedures and cost structures are likewise examined.
The Global Cold Chain Logistics market 2035
research provides a basic overview of the industry including definitions,
classifications, applications and industry chain structure. The Global Cold Chain
Logistics MarketShare analysis is provided for the international
markets including development trends, competitive landscape analysis, and key
regions development status. Development policies and plans are discussed as
well as manufacturing processes and cost structures are also analyzed. This
report also states import/export consumption, supply and demand Figures, cost,
price, revenue and gross margins. For each manufacturer covered, this report
analyses their Cold Chain Logistics manufacturing sites, capacity, production,
ex-factory price, revenue and market share in global market.
Global Cold Chain Logistics Market Highlights:
The Cold Chain Logistics Market report offers an
in-depth analysis of the Cold Chain Logistics industry and the demand drivers
by highlighting information on several aspects of the market. Prudent Markets
addresses all these aspects and provides the latest scoop and detailed
eye-opening study on all major & emerging business segments. In addition to
this, the report sheds light on the industry developments by key players, which
are contributing to the expansion of this industry. The development scope,
feasibility study, Cold Chain Logistics market concentration, and maturity
analysis is elaborated in this report.
Information given in the research report pertains
to different technological advancements introduced in recent years, which
allows for a meticulous analysis of the industry and offers a more
comprehensive understanding to the readers.
The outbreak of covid-19 in the global market has
made companies uncertain about their future scenario as the prolonged lock-down
finds a serious economic slump. The latest survey on COVID-19 Outbreak-Global Cold
Chain Logistics Market is conducted to provide hidden gems performance
analysis. Essential growth factors and study of Basis points [BPS] have been
discussed in the following report. Research Report explains a detailed overview
of market dynamics, segmentation, product portfolio, business plans, and the
latest development in the industry.
Out research methodology is robust and includes
data triangulation based on bottom-up and top-down approaches. We validated the
approximate market number with the help of primary research. Secondary research
was conducted to find out detailed information about mergers and acquisitions,
collaborations, joint ventures, and agreements. At the same time, we have
derived significant information about the market dynamics associated with
growth drivers, trends, and obstacles.
It offers figurative estimations for upcoming
years on the basis of the recent developments and historic data. For gathering
information and estimating revenue for all segments, researchers have used
top-down and bottom-up approaches. On the basis of data collected from primary
and secondary research and trusted data sources the report will help both
existing and new aspirants for Cold Chain Logistics market to figure out and
study the market’s needs, market size, and competition.
Regional Analysis of Cold Chain Logistics Market
Cold Chain Logistics Market Report states
import/send out utilization, organic market Figures, cost, value, income and
gross edges. This report also studies the global Cold Chain Logistics market
status, competition landscape, market share, growth rate, future trends, market
drivers, opportunities and challenges, sales channels and distributors.
Regionally, this report categorizes the production, apparent consumption,
export and import of Cold Chain Logistics in North America, Europe, China,
Japan, Southeast Asia and India.
Market Segmentation:
Cold Chain Logistics Market for Vaccines
(including Coronavirus (COVID-19 Vaccine)) by Type of Services, Mode of
Transportation, Holding Temperature, Type of Packaging Methods and Key
Geographical Regions: Industry Trends and Global Forecasts, 2021-2030
Key Players Covered:
Cryoport, DHL Express, GAC, Lynden International
Logistics, PAREXEL, United Parcel Service and Yusen Logistics.
Key Insights
·
Prevalence of prominent autoimmune disorders for
key countries or key regions
·
New product launch
·
Technological advancements
·
Recent industry developments such as
partnerships, mergers, and acquisitions
Browse Complete Report at: https://www.rootsanalysis.com/reports/cold-chain-logistics-for-vaccines.html
About Roots Analysis
Roots Analysis is a global leader in the pharma /
biotech market research. Having worked with over 750 clients worldwide,
including Fortune 500 companies, start-ups, academia, venture and strategic
investors for more than a decade, we offer a highly analytical / data-driven
perspective to a network of over 450,000 senior industry stakeholders looking
for credible market insights. All reports provided by us are structured in a
way that enables the reader to develop a thorough perspective on the given subject.
Apart from writing reports on identified areas, we provide bespoke research /
consulting services dedicated to serve our clients in the best possible way.
Contact Details
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Website: https://www.rootsanalysis.com/
The rising interest in medical robots in healthcare domain
for different purposes has prompted the industry to leverage the expertise of
players developing surgical robots and rehabilitation robots.
The global medical
robotics market size is estimated to grow from $ 10.1 billion in 2024 to $
31.3 billion by 2035, at a CAGR of 10.8% during the forecast period, till 2035.
Medical robots are medical devices that are programmed to
assist medical professionals in a variety of tasks, such as patient
interaction, patient welfare assessment, operating in hazardous and emergency
circumstances, data mining to enhance the efficiency of a pharmacy, and
disinfection of hospital rooms. As a result, these robots are being utilized in
healthcare for different purposes, including carrying out logistic tasks,
execute surgical procedures, support patient rehabilitation and provide care to
the patients via remote commands to the robot. It provides invaluable
assistance in activities that were once challenging for humans to undertake,
thereby, strengthening the healthcare system.
Nowadays, medical robots are well-known for their
contribution to minimally invasive or laparoscopic surgical processes. This can
be attributed to the fact that the conventional approach followed by the
surgeons to conduct invasive surgeries involves the usage of their hands and
wide range of surgical instruments. However, it involves the need to make
larger incision in the patient’s body resulting in heavy blood loss,
post-surgical scarring, increased risk of infection (even during the healing
period) and some other medical complications associated with surgeries that are
being conducted on different anatomical areas. The incorporation of surgical
robots in such interventional surgical procedures has led to circumvention of
the aforementioned challenges of conventional surgeries by performing
procedures through small incisions (even in hard-to-reach areas).
Applications of Medical Robots in Healthcare
The healthcare sector, worldwide, is exploring the potential
of robotics, particularly for minimally invasive surgeries, diagnostic and
rehabilitation purposes. It is worth
noting that during Covid-19 pandemic, several parts of the world (including
China, US, Mexico, India and some European countries) started leveraging robots
to spray disinfectants, hand sanitizer-dispensing robots, patrol robots (robots
for checking temperature of visitors in hospitals), robot as chefs, robots in
food service and preparation, robots for delivering groceries and ninja robots
(which can deliver essential items to those infected).
This has demonstrated some significant improvements in
healthcare system and contributed to the prevention of the spread of
coronavirus infection. Moreover, the use of robots in healthcare is rapidly
gaining traction due to their ability to overcome transportation barriers.
Hence, with the expanding use cases and continuous advancements in medical
robotics, the adoption of medical robots in healthcare is poised to transform
the way medical care is delivered, bringing about significant benefits for
patients, healthcare providers, and society as a whole.
The rising interest of stakeholders in this domain is
reflected by the increasing number of partnerships established in the recent
past; notably, the maximum number of deals were signed in 2021.
During our research, we came across several partnerships
that have been established by various stakeholders engaged in the surgical
robots domain, during the period 2019-2023. A steady growth in the partnership activity has been observed in recent
years; acquisitions have been the most prominent type of partnership model
adopted by surgical robot developers based in the US.
It is worth mentioning that eight deals were signed with
non-industry players in year 2023; examples include (in reverse chronological
order, product / technology utilization agreements) collaborations between
Wandercraft and Brazilian Health Authority (July 2023), Trexo Robotics and
Keystone Education Group (June 2023), and CYBERDYNE and Coopselios (May 2023).
During our research, we came across several partnerships
that have been established by various stakeholders engaged in the
rehabilitation robotics domain, during the period 2017-2023. With the growing
demand for rehabilitation robots amongst patients, several types of strategic
deals have been inked in this domain; since 2017, the majority (26%) of
partnerships signed were distribution agreements.
Most of the agreements (72%) were signed between players
based in different countries (international agreements). Majority of such
agreements inked by rehabilitation robot developers based in Asia-Pacific were
inked by players headquartered in China and Japan. Notable examples of such
deals include (in reverse chronological order) agreements between Fourier
Intelligence and MyndTec (May 2023), H-Robotics and Rehabmart (November 2022),
and Angel Robotics and Daehan Rehabilitation Hospital (August 2022).
Thank you for reading our report. Kindly get in touch with
us to know more about the report or to receive a customized copy of it. Our
team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/medical-robotics-market.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech
market research. Having worked with over 750 clients worldwide, including
Fortune 500 companies, start-ups, academia, venture capitalists and strategic
investors for more than a decade, we offer a highly analytical / data-driven
perspective to a network of over 450,000 senior industry stakeholders looking
for credible market insights.
We specialise in analysing areas which have lacked quality
research so far or require more focused understanding within the broader
industry. All our reports are structured in a way to enable the reader develop
a thorough perspective on the given subject. Apart from writing reports on
identified areas, we also provide bespoke research / consulting services
dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The
leadership team brings a wealth of experience within the sector. Their
collective experience in pharmaceutical / affiliated domains allows us to
tackle various areas of research in a structured way. We also regularly
leverage our global network of experts who hold senior leadership positions in
reputed firms and organisations worldwide.
Contact:
Roots Analysis
Gaurav
Chaudhary
+1
(415) 800 3415
+44
(122) 391 1091
Website: https://www.rootsanalysis.com/
The liquid biopsy market size is estimated to
grow from USD 6.09 billion in 2024 to USD 29.8 billion by 2035, growing at a
CAGR of 15.53% from 2024 to 2035.
Roots analysis research has recently released
expansive research titled liquid biopsy market guarantees you will remain
better informed than your competition.
Liquid biopsy market report gives explanation
about the different segments of the market analysis which is demanded by
today’s businesses. Key players are taking actions such as developments,
product launches, acquisitions, mergers, joint ventures and competitive
analysis in the industry. All the market aspects are estimated and analysed by
a team of innovative, enthusiastic and motivated researchers and analysts so
that nothing lefts uncovered in the report. Global Liquid Biopsy
Marketresearch report, it becomes easy to figure out brand awareness and
insight about the brand and product among potential customers.
Key
market segmentation:
Liquid biopsy market: distribution by type of product and / or device
offered (botox, dermal fillers, chemical peels,
body contouring, gluteal implants, hair removal, breast implants and
other products and / or devices), type of procedure (non-invasive, minimally
invasive and invasive), end user (hospitals, clinics / med spas and dermatology
/ cosmetology centers, and other end users), gender (male and female),
distribution channel (direct distribution and indirect distribution)
Major
key player liquid biopsy market
ArcherDX,
CellMax Life, ClearNote Health, DiaCarta, Personal Genome Diagnostics, Singlera
Genomics, Sysmex Inostics and Helio Genomics.
Objective
of liquid biopsymarket:
Every firm in the liquid biopsy market has
objectives but this market research report focus on the crucial objectives, so
you can analysis about competition, future market, new products, and
informative data that can raise your sales volume exponentially.
·
Size of the liquid biopsy market and
growth rate factors.
·
Important changes in the future liquid biopsy industry.
·
Top worldwide competitors of the market.
·
Scope and product outlook of liquid biopsy market.
·
Developing regions with potential growth in
the future.
·
Tough challenges and risk faced in market.
·
Global liquid biopsy top
manufacturers profile and sales statistics.
Key takeaways from the liquid biopsy market
report:
·
Detailed considerate of liquid biopsy market-particular
drivers, trends, constraints, restraints, opportunities and major micro
markets.
·
Comprehensive valuation of all prospects
and threat in the
·
In depth study of industry strategies for
growth of the cardiovascular genetic testing market-leading players.
·
Liquid biopsy market latest
innovations and major procedures.
·
Favorable dip inside vigorous high-tech and
market latest trends remarkable the market.
·
Conclusive study about the growth
conspiracy of market for forthcoming years.
Liquid biopsy market country level analysis
The countries covered in the liquid
biopsy market report are u.s., canada and mexico in north america, brazil,
argentina and rest of south america as part of south america, germany, italy,
u.k., france, spain, netherlands, belgium, switzerland, turkey, russia, rest of
europe in europe, japan, china, india, south korea, australia, singapore,
malaysia, thailand, indonesia, philippines, rest of asia-pacific (apac) in
asia-pacific (apac), south africa, saudi arabia, u.a.e, israel, egypt, rest of
middle east and africa (mea) as a part of middle east and africa (mea).
Frequently asked questions
To know more about this premium
research report, visit @ https://www.rootsanalysis.com/reports/liquid-biopsy-and-nicd-market/279.html
About roots analysis
Roots analysis is a global leader in
the pharma / biotech market research. Having worked with over 750 clients
worldwide, including fortune 500 companies, start-ups, academia, venture
catalysts, and strategic investors for more than a decade, we offer a highly
analytical / data-driven perspective to a network of over 450,000 senior
industry stakeholders looking for credible market insights. All reports
provided by us are structured in a way that enables the reader to develop a
thorough perspective on the given subject. Apart from writing reports on
identified areas, we provide bespoke research / consulting services dedicated
to serving our clients in the best possible way.
The research efforts are driven by a
global team. The leadership team brings a wealth of experience within the
sector. Their collective experience in pharmaceutical / affiliated domains
allows us to tackle various areas of research in a structured way. We also
regularly leverage our global network of experts who hold senior leadership
positions in reputed firms and organizations worldwide.
All our analysts are trained to
produce high-quality research work. They are continuously mentored by senior
experts to present an original, unbiased and informed perspective on pressing
issues in the industry. On any particular subject, we bring together the best
available resources to ensure highest quality in all our reports.
Contact details
Roots analysis
Gaurav
chaudhary
+1
(415) 800 3415
+44
(122) 391 1091
Website: https://www.rootsanalysis.com/
Molecular diagnostics aids in early detection of diseases by utilizing the genetic information of a patient in order to facilitate therapeutic monitoring and improve the overall patient healthcare outcome.
The global
molecular diagnostics marketsize is estimated to grow from
$15.9 billion in 2024 to $30.9 billion by 2035, at a CAGR of 6.2% during the
forecast period, till 2035.
Molecular
diagnostic solutions are advanced techniques and tools used to analyze
biological markers in the genome and proteome of the individual’s genetic code.
These diagnostic solutions are essential for detecting and monitoring diseases,
identifying genetic predispositions, and guiding the patients for personalized
treatment plans. The core technologies include polymerase chain reaction,
next-generation sequencing and microarrays. Molecular diagnostic solutions are
pivotal across various medical fields, including oncological disorders,
infectious diseases, genetic testing, and personalized medicines. These
solutions enhance the accuracy of diagnoses, enable and support tailored
treatment strategies aiming to ultimately improve diagnostic outcomes and improving
public health.
In the
following sections, we explore the various technologies used by molecular
diagnostic solutions.
Nucleic
Acid Amplification Tests– This technology amplifies the DNA sequences to detectable levels. Some of the
key examples include qPCR, RT-PCR and loop-mediated isothermal amplification.
Sequencing
Technologies– DNA
sequencing provides comprehensive genomic insights identifying mutations and
variations in the sequence. Examples include sanger sequencing and next
generation sequencing.
Hybridization– Used for gene expression
profiling, genotyping and detecting chromosomal
abnormalities.
Examples include microarrays and fluorescence in situ hybridization.
Protein-based
Assays– Used to
identify and quantify proteins to aid in disease diagnosis and therapeutic
monitoring. Examples include mass spectrometry and immunoassays.
In the
following section, we have mentioned future perspectives / trends that are
likely to emerge in the molecular diagnostics market.
·
Integration
of artificial intelligence (AI) and machine learning tools can enable
organizations to process a vast amount of genomic data, identify patterns and
make diagnostic decisions with informed accuracy. Further, AI-driven tools can
tailor diagnostics and treatments to individual patient requirements by
integrating genetic, proteomic, and clinical data.
·
Ongoing
improvements in next-generation sequencing have made such services more
affordable, facilitating its widespread adoption in clinical settings.
Moreover, technologies, such as long-read sequencing aim to improve the
accuracy of genome assembly and identification of structural variants. On the
other hand, advancements in single cell sequencing enables detailed analysis of
individual cells, providing insights into cellular heterogeneity and disease
mechanisms.
·
Recent
shift towards portable, easy-to-use devices that provide quick and accurate
results at the point of care or at-home settings has been pivotal in providing
enhanced healthcare delivery in remote and resource-limited settings thereby,
reducing the need for centralized laboratory facilities. Further, such
solutions encourage patient participation through home-based testing and
digital health solutions.
Using our
proprietary approach, we identified the parameters pertaining to porter’s five
forces; these were further evaluated to determine their impact on the molecular
diagnostics market
Porter’s
Five Forces Analysis is a qualitative framework that determines the strengths
and weaknesses of industries by analyzing five competitive forces that contour
every industry. It can be applied to any segment of the industry to comprehend
the competitive landscape in a sector and deploy relevant strategies in order
to increase the overall profitability of the stakeholders.
The key
parameters that are likely to impact the molecular diagnostics market, to help
determine industrial strengths and weaknesses have been mentioned below:
·
Threat
of New Entrants-
It refers to the threats posed by new competitors to existing players in the
market.
·
Bargaining
Power of Buyers-
This force analyzes how much pressure a consumer / customer can exert on
providers so as to get better services and high-quality products at a lower
cost.
·
Bargaining
Power of Suppliers- The force analyzes the extent to which the molecular diagnostics solution
providers can put pressure on the buyers by raising the prices, lowering the
quality, and reducing the availability of the supplies.
·
Threat
of Substitute Products- This force analyzes the extent to which a product / service can be replaced
by similar class of alternative products / services.
·
Rivalry
among Existing Competitors- This force examines the current competition in the market and is determined
by the number of existing competitors in the domain.
Thank you
for reading our report. Kindly get in touch with us to know more about the
report or to receive a customized copy of it. Our team will ensure the report
is tailored according to your needs.
To
view more details on this report, click on the link
https://www.rootsanalysis.com/reports/molecular-diagnostics-market.html
About Roots Analysis
Roots
Analysis is a global leader in the pharma / biotech market research. Having
worked with over 750 clients worldwide, including Fortune 500 companies,
start-ups, academia, venture capitalists and strategic investors for more than
a decade, we offer a highly analytical / data-driven perspective to a network
of over 450,000 senior industry stakeholders looking for credible market
insights.
We
specialise in analysing areas which have lacked quality research so far or
require more focused understanding within the broader industry. All our reports
are structured in a way to enable the reader develop a thorough perspective on
the given subject. Apart from writing reports on identified areas, we also
provide bespoke research / consulting services dedicated to serve our clients
in the best possible way.
The
research efforts are driven by a global team. The leadership team brings a
wealth of experience within the sector. Their collective experience in
pharmaceutical / affiliated domains allows us to tackle various areas of
research in a structured way. We also regularly leverage our global network of
experts who hold senior leadership positions in reputed firms and organisations
worldwide.
Contact:
Roots
Analysis
+1
(415) 800 3415
The vaccine
adjuvants marketis estimated to be worth $4.3
billion in 2022 and is expected to grow at compounded annual growth rate (CAGR)
of 2.7% during the forecast period.
Vaccines have enabled the
prevention of more than 37 million deaths due to various disease indications,
such as cholera, diphtheria, influenza, tetanus, whooping cough and measles,
between 2000 to 2019. Given the rate at
which the global population is growing and taking into consideration the
prevalent (such as the COVID-19 pandemic) and anticipated future trends, the
demand for vaccines is likely to increase significantly. According to experts,
the global vaccines market is anticipated to generate revenues worth USD 100
billion by 2025. In this regard, significant strides have been made to develop
safe and effective, next generation vaccine candidates, such as sub-unit
vaccines, recombinant vaccines, conjugate vaccines and DNA vaccines. However,
such vaccines employ purified non-living vaccine antigens (unlike their
counterparts, live attenuated and inactivated vaccines) and are, most often,
less immunogenic and require an additional aid to increase their immunogenicity
against the target antigens. As a result, a variety of vaccine adjuvants
(substances with the innate potential to augment an immune response), such as
AS04 (Cervarix®), MF59 (Fluad®), AS01B (Shingrix®) and CpG 1018 (Heplisav-B®),
have been discovered and are now available for the development of more
effective and versatile vaccine formulations.
Presently, an increasing number of
vaccines under development are incorporating vaccine adjuvants owing to various
advantages offered by such agents, including improved adaptive response to a
vaccine, guiding the type of adaptive response to produce the most effective
forms of immunity for each specific pathogen and facilitation of the use of
smaller doses of antigen. Further,
majority of the adjuvants used in human vaccines enhance humoral immunity;
however, several novel adjuvants in clinical or preclinical development are
focused on enhancing specific types of T-cell responses to generate
multifaceted immune responses required for complex indications, such as malaria
and HIV-AIDS. Currently, more than 70 companies and academic / research
institutes are engaged in the development of various types of vaccine
adjuvants. It is worth highlighting that capital investments worth over USD 5.5
billion have been made by various private and public sector investors during
the last five years to fund the product development activity in this domain. In
addition, there have been several recently reported instances of collaborations
between industry / academic stakeholders to advance the development of various
vaccine adjuvants. Driven by the increasing demand for safe and effective
vaccines, ongoing pace of innovation in this field and financial support from
the investors, the vaccine adjuvants market is likely to witness substantial
growth in the mid to long-term.
Vaccine Adjuvant Developers – Current
Market Landscape
The continuously growing
pharmaceutical industry and demand for safe and effective vaccines amidst the
pandemic has led to an increase in the development of vaccine adjuvants. As a
result, vaccine developers are trying to incorporate vaccine adjuvants with
their respective product to increase its efficacy and efficiency. Moreover,
vaccine adjuvants play an important role in improving adaptive response to a
vaccine, guiding the type of adaptive response to produce the most effective
forms of immunity for each specific pathogen and facilitation of the use of
smaller doses of antigen. During our research, we identified more than 70
companies that are actively involved in developing close to 110 vaccine
adjuvants.
Thank you for reading our report. Kindly get in touch with us to know more
about the report or to receive a customized copy of it. Our team will ensure
the report is tailored according to your needs.
To view more details on this
report, click on the link
https://www.rootsanalysis.com/reports/metabolomics-services-market.html
About Roots Analysis
Roots Analysis is a global leader
in the pharma / biotech market research. Having worked with over 750 clients
worldwide, including Fortune 500 companies, start-ups, academia, venture
capitalists and strategic investors for more than a decade, we offer a highly
analytical / data-driven perspective to a network of over 450,000 senior
industry stakeholders looking for credible market insights.
We specialise in analysing areas
which have lacked quality research so far or require more focused understanding
within the broader industry. All our reports are structured in a way to enable
the reader develop a thorough perspective on the given subject. Apart from
writing reports on identified areas, we also provide bespoke research /
consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by
a global team. The leadership team brings a wealth of experience within the
sector. Their collective experience in pharmaceutical / affiliated domains
allows us to tackle various areas of research in a structured way. We also
regularly leverage our global network of experts who hold senior leadership
positions in reputed firms and organisations worldwide.
Contact Details
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Website: https://www.rootsanalysis.com/
ADC Linker and Conjugation Technologies have emerged as a
versatile solution for the development of more efficient and stable antibody
drug conjugates.
The global ADC
technology market size is estimated to grow from USD 1.18 billion in 2023
to USD 4.37 billion by 2035, representing a CAGR of 11.5% during the forecast
period 2023-2035.
Conventional anti-cancer therapeutics are characterized by
on-target-off-tumour toxicities, making such therapies detrimental to patients.
This limitation led to the development of more efficacious and targeted therapy
such as antibody drug conjugates (ADCs). ADCs are a complex and versatile form
of anti-cancer therapy, which have been proven to be more effective and less
toxic to patients.
Such interventions are designed to identify specific
antigens that are expressed on the surface of target (cancer) cells so that the
effects of the cytotoxin / drug are focused on the elimination of only the
tumour cells. Owing to the target
specificity component, the approach reduces the chances of damaging normal
cells. Over the years, this class of therapeutics has undergone several
improvements, most of which were focused on how the highly potent cytotoxic
component could be attached to the segment that confers specificity (the
antibody). The physical attachment of the aforementioned components is
facilitated in a process that is commonly referred to as conjugation, or
bioconjugation. This chapter features brief descriptions of the different types
of linker and conjugation technologies that are used in the development of
ADCs. Further, it offers insights from the industry’s perspective, concerning
the future of these technologies.
Antibody Drug Conjugates
Antibody drug conjugates (ADCs) are an upcoming class of
targeted therapeutic agents. Fundamentally, these complex biotherapeutic
entities demonstrate the combination of target specificity of an antibody and
therapeutic features of a chemotherapy / cytotoxic drug.
Components of ADCs
The failure of first-generation ADCs has been attributed to
the use of unstable acid-labile linkers, which are prone to degradation in
acidic environment of the cell. Since then, linker technologies have undergone
significant advances and improvements. Early linkers, which were derived from
the acid cleavable hydrazones, could be cleaved at non target sites and
thereby, were known to cause systemic toxicity. To overcome these challenges,
second-generation linkers, with improved stability, were developed. Further,
third-generation conjugation technologies were developed to generate
site-specific ADCs without any engineering / modification of the conjugation
site.
It is evident that the evolutionary advances in conjugation
and linker technologies have enabled the development of viable treatment
options. Such improvements have significantly altered the therapeutic potential
and likely applications of ADCs. In other words, succeeding generations of
conjugated drugs, based on improved technologies are more selective in
targeting diseased cells and have broader therapeutic windows.
Despite the current opinion on the superiority of this class
of therapeutics, the existing understanding of the biochemical, immunological,
pharmacological, and molecular aspects of ADCs needs to be furthered in order
to design and develop better versions of these products. The choice of a
suitable target antigen and cytotoxic payload is important, however, the
conjugation approach used and linker chemistry involved are equally crucial
elements for manufacturing viable leads. In fact, linker instability and
product heterogeneity (variations in DAR between conjugate molecules
manufactured in a singular batch) are known to severely compromise ADC efficacy
and therapeutic window, which may cause difficulties in the lead optimization
for clinical application, eventually resulting in trial failure. As a result,
there are a number of efforts directed towards the development of better / more
stable linkers and site-specific conjugation methods that enable manufacturers
to synthesize homogeneous batches of ADCs. The demand for ADCs is on the rise.
In this context, it is important to mention that ADCs have also been proven to
be more effective in treating bacterial infections than conventional
antibiotic-based treatment regimens.
Another popular field that has emerged as
a potential application area for ADCs, is chronic clinical conditions. In this
case, selective payload delivery, using ADCs, to disease-associated biological
targets has been demonstrated to reduce side-effects. In terms of novel
treatment paradigms, ADCs are also being investigated in combination with
small-molecule drugs. The growing popularity of this approach can be attributed
to its potential to overcome the concerns related to multi-drug resistance.
With the growing demand for ADCs, therapy developers, as indicated earlier, are
striving to discover and develop better conjugation methods and the means to
further tap into the vast potential of these therapeutics.
Thank you for reading our report. Kindly get in touch with
us to know more about the report or to receive a customized copy of it. Our
team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/adc-technologies-market/287.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech
market research. Having worked with over 750 clients worldwide, including
Fortune 500 companies, start-ups, academia, venture capitalists and strategic
investors for more than a decade, we offer a highly analytical / data-driven
perspective to a network of over 450,000 senior industry stakeholders looking
for credible market insights.
We specialise in analysing areas which have lacked quality
research so far or require more focused understanding within the broader
industry. All our reports are structured in a way to enable the reader develop
a thorough perspective on the given subject. Apart from writing reports on
identified areas, we also provide bespoke research / consulting services
dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The
leadership team brings a wealth of experience within the sector. Their
collective experience in pharmaceutical / affiliated domains allows us to
tackle various areas of research in a structured way. We also regularly
leverage our global network of experts who hold senior leadership positions in
reputed firms and organisations worldwide.
Contact:
Roots Analysis
Gaurav
Chaudhary
+1
(415) 800 3415
+44
(122) 391 1091
Website: https://www.rootsanalysis.com/
The global mRNA therapeutics and mRNA vaccine market is
witnessing steady growth, estimated to be worth USD 51.3 billion in 2023.
In recent years, the mRNA vaccine and
therapeutics markethas grown significantly,
driven by increasing demand for targeted therapies to treat diseases that are
difficult to address with conventional drugs. Messenger RNA (mRNA), a
single-stranded ribonucleic acid that encodes proteins, has emerged as a
revolutionary drug class for managing infectious, chronic, and oncological
disorders. Pharmaceutical companies have recognized the potential of mRNA-based
therapies, particularly for treating conditions such as COVID-19, genetic
disorders, cancer, and other infectious diseases.
Despite its promise, the market faces challenges. Stringent
regulatory guidelines and the availability of pre-existing vaccines based on
other technologies have contributed to a decline in market momentum.
Additionally, as the COVID-19 pandemic transitions into an endemic phase, the
demand for mRNA vaccines is expected to decrease, contributing to a potential
downturn in the market during the forecast period.
Competitive
Landscape of the mRNA Therapeutics and Vaccine Market
Currently, the mRNA therapeutics
and vaccine market landscape features more than 35 companies engaged in
evaluating over 195 mRNA therapeutics and mRNA vaccines across different
clinical and development stages. In the coming years, several pharmaceutical
companies such as Moderna, Merck, Sanofi, and Daiichi Sankyo will enroll in
strategic partnerships with mRNA-based therapeutics and vaccine developers to
expand their therapy development capabilities.
Key
Report Takeaway
⬝
The pipeline features
several drugs, which are being investigated across different phases of
development; over 75% of the pipeline candidates are designed for delivery via
the intramuscular and intravenous routes.
⬝
The market's evolution
is likely to be driven by the rising need for novel drug candidates; we expect
the future opportunity to be well-distributed across various routes of
administration, therapeutic areas, and key regions.
⬝
Several investors, having
realized the opportunity within this upcoming segment, have invested over USD
11 billion across various funding rounds in the past nine years.
⬝
More than 345,000
patients have been recruited / enrolled in clinical trials registered for this
novel class of therapies across different geographies.
⬝
Stakeholders are
actively upgrading their existing capabilities to further enhance their
respective product pipelines and comply with the evolving industry benchmarks.
⬝
The growing interest
is evident from the rise in partnership activity since 2021; clinical trial
agreements have emerged as the most common type of partnership model adopted by
drug developers.
⬝
With over 195
candidates under development, mRNA therapeutics, and vaccines currently
represent one of the fastest-growing drug classes in the pharmaceutical market.
⬝
Big pharma players
have undertaken several initiatives, from proprietary product development to
strategic investments, to tap the lucrative opportunity in this rapidly growing
market.
mRNA
Therapeutics and Vaccine Market Segments
Based on the research report, Roots Analysis has segmented
the mRNA Therapeutics and Vaccine market into the types of secondary packaging,
primary packaging, and key geographical regions.
⬝ mRNA
Therapeutics and Vaccine Market, Based on Expertise
⬝ mRNA
Therapeutics
⬝ mRNA
Vaccines
⬝ mRNA
Therapeutics and Vaccine Market, Based on Route of Administration
⬝ Intravenous
⬝ Intramuscular
⬝ Intranasal
⬝ Others
⬝ mRNA
Therapeutics and Vaccine Market, Based on Key Geographical Regions
⬝ North
America
⬝ Europe
⬝ Asia-Pacific
⬝ Middle
East and North Africa
⬝ Latin
America
⬝ Rest
of the World
mRNA
Therapeutics and Vaccine Market Geographical Outlook
The mRNA therapeutics and vaccine
market based on geographical region is segmented into North America, Europe,
Asia-Pacific, Latin America, the Middle East, North Africa, and the rest of the
world. North America is dominating the mRNA therapeutic and vaccine market,
holding the largest share of overall revenue. The National Institutes of Health
supports research and development of mRNA therapeutics through grants even
before the pandemic. Active support from regulatory authorities and government
initiatives is driving the market in North America during the forecast period.
mRNA
Therapeutics and Vaccine Market Key Players
Examples of the key companies engaged in the mRNA
Therapeutics and Vaccine market (which have also been profiled in the market
report; the complete list of the companies is also included in the full report)
include:
▪
IMMORNA
▪
BioNTec
▪
eTheRNA
▪
Stemirna Therapeutics.
▪
Moderna
▪
Omega Therapeutics
▪
Chimeron Bio
▪
CureVac
▪
RNACure
It is worth noting the ongoing
developments and collaborations in the mRNA therapeutics and vaccine market,
which anticipate steady growth. An example of such a partnership includes:
⬝
In August, Moderma and CARsgen Therapeutics entered
into a collaboration to combine their respective mRNA therapeutics cancer
vaccine with a solid tumor CAR-T cell therapy for the treatment of individuals
with multiple cancers.
⬝
In June 2023, Providence Therapeutics collaborated with
the University Health Network (UHN) to develop mRNA-based therapeutics and
vaccines to treat patients with cancer and infectious diseases.
In April 2023, Moderna and IBM collaborated to explore advanced next
generation technologies such as artificial intelligence and quantum computing
in order to enhance their mRNA research and science.
To get market data, market insights,
financial statements, and a comprehensive analysis of themRNA Therapeutics and mRNA Vaccine market, please contact [email protected]
You Can Order the Complete Report on the MRNA
Therapeutics and Vaccine Market Online by Clicking On the Given Link
https://www.rootsanalysis.com/reports/mrna-therapeutics-and-vaccines-market.html
About Roots Analysis
Roots
Analysisis a global leader in the pharma
/ biotech market research. Having worked with over 750 clients worldwide,
including Fortune 500 companies, start-ups, academia, venture capitalists, and
strategic investors for over a decade, we offer a highly analytical /
data-driven perspective to a network of over 450,000 senior industry
stakeholders looking for credible market insights. All reports provided by us
are structured in a way that enables the reader to develop a thorough
perspective on the given subject. Apart from writing reports on identified
areas, we provide bespoke research /
consulting servicesdedicated to serving
our clients in the best possible way.
Contact
US
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: [email protected]or [email protected]
Website: https://www.rootsanalysis.com
The Global Cell Therapy Manufacturing Market report provides a thorough analysis of the Cell Therapy Manufacturing market, offering valuable insights for investors, stakeholders, and business strategists for the forecast period of 2024-2035. It presents the projected growth rate and market value for the coming years.
The cell
therapy manufacturing market was valued at $4.5 billion in 2022 and is
expected to grow at a compound annual growth rate (CAGR) of 12% during the
forecast period. The report also helps market participants, new players, and
stakeholders understand how to navigate the challenges posed by the COVID-19
pandemic. It offers a detailed analysis of the pandemic's impact on the market
and its key segments, as well as an assessment of both current and future
effects on market growth.
Research Report
on the Cell Therapy Manufacturing Market Addresses the Following Key Questions:
Market
Overview:
The report bifurcates the Cell Therapy Manufacturing
market on the basis of different product types, applications, end-user
industries, and key regions of the world where the market has already
established its presence. The report accurately offers insights into the
supply-demand ratio and production and consumption volume of each segment.
The Regional Landscape section of the Cell Therapy
Manufacturing report provides in-depth insights into the regulatory
environment, current and emerging market trends, production and consumption
patterns, supply and demand dynamics, import/export activities, and the
presence of key players in each region.
The Competitive Landscape section offers valuable,
actionable information about the business environment within the Cell Therapy
Manufacturing market, including detailed profiles of the leading market
players. The report covers market share, product offerings, pricing strategies,
and strategic actions such as mergers, acquisitions, joint ventures,
collaborations, partnerships, product launches, and brand promotions.
Additionally, the report highlights the measures taken by key companies to
address the impact of the COVID-19 pandemic.
To know more
about the report, visit @ https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html
Thank you for reading our report. To know more about
the customization feature, please get in touch with us, and our team will
ensure the report is customized to meet your requirements.
About roots analysis
Roots analysis is a global leader in the pharma /
biotech market research. Having worked with over 750 clients worldwide,
including fortune 500 companies, start-ups, academia, venture catalysts, and
strategic investors for more than a decade, we offer a highly analytical /
data-driven perspective to a network of over 450,000 senior industry
stakeholders looking for credible market insights. All reports provided by us
are structured in a way that enables the reader to develop a thorough
perspective on the given subject. Apart from writing reports on identified
areas, we provide bespoke research / consulting services dedicated to serving
our clients in the best possible way.
The research efforts are driven by a global team. The
leadership team brings a wealth of experience within the sector. Their
collective experience in pharmaceutical / affiliated domains allows us to
tackle various areas of research in a structured way. We also regularly
leverage our global network of experts who hold senior leadership positions in
reputed firms and organizations worldwide.
All our analysts are trained to produce high-quality
research work. They are continuously mentored by senior experts to present an
original, unbiased and informed perspective on pressing issues in the industry.
On any particular subject, we bring together the best available resources to
ensure highest quality in all our reports.
Contact details
Roots
analysis
Gaurav chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Website: https://www.rootsanalysis.com/